Answers are grounded in this paper and cite their sources.
IL-17A is a primary driver of skin pathology in patients with psoriasis, and serum BD-2 is an easily measurable biomarker of IL-17A-driven skin pathology.
No takes yet. Share an insight, caveat, or question.
Kolbinger et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: